Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

450.97 +0.60 (+0.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
53 54 Next >
2 Growth Stocks That Might Be Too Cheap to Ignore
The sky is the limit for these healthcare companies. 
Via The Motley Fool
2 Supercharged Growth Stocks to Invest In Before the Next Bull Market
Whatever the market does in the next few months, these stocks have plenty of room left to run. 
Via The Motley Fool
3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 
Via InvestorPlace
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Vertex Pharmaceuticals Stock: Bear vs. Bull
Vertex has reached a key moment in its story. 
Via The Motley Fool
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
CRISPR stock has climbed more than 40% so far this year. 
Via The Motley Fool
Vertex to Announce Second Quarter 2023 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Buying These 3 Stocks Could Be the Smartest Investing Move You'll Ever Make
Buying these stocks now could pay off handsomely over the long run. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both companies have therapies that should help grow revenue and earnings for years. 
Via The Motley Fool
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
This company has several catalysts for growth coming up, with more on the way. 
Via The Motley Fool
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
2 Unstoppable Growth Stocks That Could Turn $20,000 into $100,000 by 2030
These one-of-a-kind businesses have an edge over the competition that could steadily push their stock prices in the right direction through the end of the decade and beyond. 
Via The Motley Fool
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
2 Market-Beating Stocks With Major Catalysts on the Way
Can these companies keep climbing? 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
All three of these stocks should be huge winners over the long run. 
Via The Motley Fool
2 Magnificent Growth Stocks to Buy Before the Next Bull Market
A bull market could be the tip of the iceberg for these businesses. 
Via The Motley Fool
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
2 Biotech Stocks That Could Help Make You a Fortune
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.